Bactericidal efficacy of ABI-0043, a novel rifamycin, in a murine pneumococcal pneumonia model.
Novel rifamycins such as ABI-0043, ABI-0369, and ABI-0699 had comparable in vivo bactericidal activity with ceftriaxone against a penicillin-G-resistant, mefA-positive Streptococcus pneumoniae in a murine pneumonia model. ABI-0043 demonstrated a dose-dependent response with a high correlation to bacterial kill (+0.1 to -3.7 log 10CFU).
Lee
Su Young
SY
Center for Anti-Infective Research and Development, Hartford Hospital, 80 Seymour Street Hartford, CT 06102-5037, USA.
Tessier
Pamela R
PR
Murphy
Christopher K
CK
Nicolau
David P
DP
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002443:Ceftriaxone / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D005260:Female; D051379:Mice; D008813:Mice, Inbred ICR; D010403:Penicillin Resistance; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy*; D012294:Rifamycins / Q000627:therapeutic use*
C518212:ABI 0043; D000900:Anti-Bacterial Agents; D012294:Rifamycins; D002443:Ceftriaxone